Source BioScience

Name

Source BioScience

Legal name

SourceBio International plc

Website

https://sourcebiointernational.com

Company type

Public

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Clinical Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)

akta.pro secondary industries

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Microbiology & Sterility Assurance (Bioburden/Endotoxin/Sterility) (HLAGADAE)

Keywords

• Clinical diagnostics services
• DNA sequencing services
• Histopathology testing
• Stability storage testing
• COVID-19 PCR testing

Headquarters

HQ city

Nottingham

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Infectious Disease Testing: COVID-19 testing services for commercial enterprises, private healthcare groups, NHS and DHSC. Includes employee testing solutions, direct-to-consumer home test kits (Fit to Fly, Test to Release, 2 & 8 Day International Travel approved tests), and venue testing. Major revenue contributor in 2021.
2. Healthcare Diagnostics: Histopathology cancer screening and clinical diagnostic services for NHS and private healthcare across UK and Ireland. Core division returning to pre-Covid trading levels.
3. Genomics: DNA sequencing services for pharmaceutical and biotechnology companies, academia, contract research organisations (CROs) and other research groups in UK, Europe and North America.
4. Stability Storage: Shelf-life testing services and equipment for pharmaceutical and biotechnology companies, contract manufacturers and analytical testing companies primarily in UK, Ireland and USA.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

SourceBio International is an integrated laboratory services provider operating four core business units: Healthcare Diagnostics (histopathology and digital pathology for NHS and private healthcare), Genomics (DNA sequencing for pharma, biotech, academia and CROs), Stability Storage (shelf-life testing services and equipment for pharma and biotech), and Infectious Disease Testing (COVID-19 RT-PCR, LAMP, LAMPore, lateral flow, quantitative antibody, and whole genome sequencing for NHS, DHSC, private healthcare, commercial enterprises, and consumers). Operations are ISO 15189, cGMP, HPRA and FDA accredited across the UK, Ireland and the United States.

Product overview

SourceBio International operates as an integrated laboratory services provider with four core business divisions: Healthcare Diagnostics (histopathology and clinical diagnostic services for NHS and private healthcare), Genomics (DNA sequencing services for pharma, biotech, academia, and CROs), Stability Storage (shelf-life testing for pharma and biotech companies), and Infectious Disease Testing (COVID-19 testing including RT-PCR, antigen, and whole genome sequencing). The company acquired LDPath Limited in 2022 to strengthen its digital pathology capabilities. Operations span facilities in the UK, Ireland, and the United States (San Diego).

Differentiator

Problem solved

Functional benefit

Products and services

• Infectious Disease Testing (COVID-19) COVID-19 testing services combining RT-PCR, LAMPore, LAMP, lateral flow, quantitative antibody and whole genome sequencing for screening, diagnostic and outbreak response use. Offered to NHS, DHSC, private healthcare groups, commercial enterprises, and consumers via employee testing, Fit to Fly / Test to Release / 2 & 8 Day International Travel home kits, and venue testing under ISO 15189 accreditation.
• Healthcare Diagnostics (Histopathology) Histopathology cancer screening and clinical diagnostic services for the NHS and private healthcare across the UK and Ireland, including cellular pathology testing services. Returns to pre-COVID trading levels were noted in the company's FY2021 commentary.
• Genomics (DNA Sequencing) Outsourced DNA sequencing services for pharmaceutical and biotechnology companies, academic institutions, contract research organizations (CROs), and other research groups in the UK, Europe and North America.
• Stability Storage Shelf-life stability testing services and stability storage equipment for pharmaceutical and biotechnology companies, contract manufacturers, and analytical testing companies, primarily serving the UK, Ireland and USA markets.
• LDPath Digital Pathology Services Digital pathology testing services delivered through the acquired LDPath Limited business, a London-based digital pathology testing company. Now positioned within SourceBio's Healthcare Diagnostics business unit to extend UK cellular and digital pathology capacity.
• San Diego COVID-19 qPCR Testing COVID-19 qPCR testing services operated from the SourceBio San Diego laboratory, delivering approximately 5,000 samples per day of testing capacity under cGMP, HPRA and FDA adherence for US and international clients.

Quantifiable outcome

• 82% increase in revenues to £92.4 million in 2021
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• LDPath LimitedcoreStrategic or Co-development Partner · 29 March 2022SourceBio International completed acquisition of LDPath Limited, a London-based digital pathology testing company. BGL advised on the transaction. The deal creates the largest private provider of cellular and digital pathology services in the UK, enhancing diagnostic capacity and efficiency.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• SYNLAB: SYNLAB is Europe's largest medical diagnostics services provider, offering clinical laboratory testing across pathology, microbiology, and infectious diseases across 30+ countries. Highly comparable to SourceBio's Clinical Diagnostics and Infectious Disease Testing segments and provides a direct benchmark for UK and European private clinical lab operations.
• Unilabs: Unilabs operates one of Europe's largest clinical diagnostics networks including a significant UK presence offering pathology and laboratory medicine services to the NHS and private providers. Closely comparable to SourceBio on cellular pathology services and genomic testing footprint.
• The Doctors Laboratory (TDL): TDL is a major UK-based private pathology laboratory providing clinical diagnostic testing, including histopathology and microbiology, to NHS and private customers. Direct competitor to SourceBio's Healthcare Diagnostics business in the UK cellular pathology market.

Broad incumbents

• Sonic Healthcare: Sonic Healthcare is a global diagnostics provider operating clinical laboratories across multiple continents, including histopathology and infectious disease testing. While much larger than SourceBio, it provides a direct comp on lab accreditation requirements, NHS-tendered work and oncology pathology services.
• Quest Diagnostics: Quest Diagnostics is one of the largest US-based clinical laboratory networks, providing routine and specialized diagnostic testing including infectious disease and molecular diagnostics. Comparable to SourceBio on integrated lab services model and ISO-accredited operations, though at materially greater scale.
• Laboratory Corporation of America (Labcorp): Labcorp is a leading global clinical laboratory services company with capabilities spanning routine, esoteric, and genomic testing as well as drug development services. Comparable to SourceBio across clinical diagnostics and pharma/biotech testing, while operating at significantly larger scale.
• Eurofins Scientific: Eurofins is a global testing services group with a strong clinical diagnostics and genomics arm (Eurofins Genomics) serving pharmaceutical, biotech, and academic customers. Comparable to SourceBio's Genomics and stability testing offerings and their cross-sell to pharma/biotech clients.
• Charles River Laboratories: Charles River Laboratories provides research and laboratory services to the pharma, biotech and academic sectors including genomics and drug development support. Comparable to SourceBio Genomics and Stability Storage segments serving pharma/biotech and CRO customers.

Emerging players

• Genomics plc: Genomics plc is a UK-based genomics company offering DNA sequencing and analytics services to pharma and academic customers. Comparable to SourceBio's Genomics segment in target customers and DNA sequencing technology, though on a smaller and emerging scale.
• Pharmaron: Pharmaron is a global CRO providing drug R&D services including genomics, analytical testing and stability storage for pharmaceutical and biotech customers. Comparable to SourceBio's Genomics and Stability Storage divisions serving pharma/biotech R&D workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SourceBio
• LinkedInlinkedin.com/company/source-bioscience

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Source BioScience